



# Illuminating disease- associated variation with ENCODE & Roadmap Data

John A. Stamatoyannopoulos, M.D.  
Depts. of Genome Sciences & Medicine  
University of Washington


# Genes, regulatory DNA, and epigenetic features



# Genes, regulatory DNA, and epigenetic features



# Creating deep maps of human regulatory DNA



[genome.ucsc.edu](http://genome.ucsc.edu)  
[www.uwencode.org](http://www.uwencode.org)

[www.roadmapepigenomics.org](http://www.roadmapepigenomics.org)  
[vishub.wustl.edu](http://vishub.wustl.edu)

[www.encode-roadmap.org](http://www.encode-roadmap.org)

# A global atlas of human regulatory DNA

- **>340 cell types, tissues, and developmental stages**  
*Model cell lines, Primary cells in culture*  
*Ex vivo hematopoietic cells, Fetal tissues (late 1<sup>st</sup> – late 2<sup>nd</sup> trimester)*
- **~100,000 - >250,000 DHSs per cell type** (0.5-1.5% of genome)
- **Collectively >4 million distinct elements**  
~800,000 cell type-specific, ~3,500 constitutive
- **Comprehensive annotation of known regulatory DNA**  
99% of experimentally-validated enhancers, silencers, insulators, locus control regions

Selected data

■ Roadmap 
 ■ ENCODE 
 ■ Combined 
 ■ Selected

Data points you select in the tables above will appear below for preview before viewing them in the browser.

Go to Browser

Unselect all data cell points


- Expand All
- Collapse All

|  | Data Types |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
|--|------------|-----|---------|-------------|------------|-------|---------|----------|----------|---------|---------|---------|----------|----------|--------|---------|---------|----------|--|
|  | DNase      | DGF | RNA-Seq | Methyl RRBS | Methyl-seq | H2A.Z | H3K27ac | H3K27me3 | H3K36me3 | H3K4me1 | H3K4me2 | H3K4me3 | H3K79me2 | H3K79me3 | H3K9ac | H3K9me1 | H3K9me3 | H4K20me1 |  |
| PBMC                                       |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
| Th1  |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
| Th2  |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
| Peripheral Blood Mononuclear Primary Cells |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
| Th17 Primary Cells                         |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
| Treg Primary Cells                         |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
| <b>Bone</b>                                |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
| Osteobl                                    |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
| U2OS                                       |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
| <b>BRAIN</b>                               |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
| Brain Angular Gyrus                        |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
| Brain Anterior Caudate                     |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
| Brain Cingulate Gyrus                      |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
| Brain Germinal Matrix                      |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
| Brain Hippocampus Middle                   |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
| Brain Inferior Temporal Lobe               |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
| Brain Mid Frontal Lobe                     |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |
| Brain Substantia Nigra                     |            |     |         |             |            |       |         |          |          |         |         |         |          |          |        |         |         |          |  |


**Regulatory DNA variation  
associated with common  
diseases and traits**

# Identification of disease- and trait-associated variation by GWAS

## GWAS Studies



## Distribution of GWAS SNPs vs. known genes



**GWAS disease/trait associated variants**

**X**



**Maps of regulatory DNA in >300 diverse cell and tissue types**



#1

**Disease-associated variation  
is concentrated in  
regulatory DNA**



# Disease- and trait-associated SNPs are concentrated in regulatory DNA



~1.8-fold for all replicated variants in all disorders

**>10-fold for specific disease-cell type pairings**


# The effect increases monotonically with other measures of higher quality associations



**#2**

**GWAS variants selectively  
localize in pathologically  
relevant cell types**


# Disease-associated variation clusters in pathogenic or target cell types




**#3**

**Common diseases and traits  
with known or suspected  
developmental contributions  
preferentially localize in fetal  
regulatory DNA**

# Most variants lie in regulatory DNA of fetal origin



# Fetal regulatory variants are enriched in traits & diseases with known links to intrauterine exposures





#4


Don't assume local effects

**#4**


**GWAS variants in regulatory  
DNA control distant disease-  
related genes**

# Regulatory GWAS variants linked to distant genes with causative potential

Platelet count




Chromatin interactions (ChIA-PET)




# Regulatory GWAS variants linked to distant genes with causative potential

**Platelet count**




**White blood cell count**




# Regulatory GWAS variants linked to distant genes with causative potential


## Platelet count



## Atrial fibrillation



# Regulatory GWAS variants linked to distant genes with causative potential




| Disease or trait              | <i>r</i> | Target gene | Function  | Distance (kb) |
|-------------------------------|----------|-------------|---|---------------|
| Amyotrophic lateral sclerosis | 1        | SYNGAP1*    | Axon formation; component of NMDA complex                           | 411           |
| Crohn's disease               | 1        | TRIB1*      | NF- $\kappa$ B regulation   | 95            |
| Time to first primary tooth   | 0.99     | PRDM1*      | Craniofacial development  | 452           |
| C-reactive protein            | 0.99     | NLRP3       | Response to bacterial pathogens                                     | 20            |
| Multiple sclerosis            | 0.98     | AHI1*       | White matter abnormalities  | 149           |
| QRS duration                  | 0.96     | SCN10A*     | Sodium channel involved in cardiac conduction                       | 181           |
| Breast cancer                 | 0.96     | TACC2*      | Tumor suppressor  | 411           |
| Schizophrenia/brain imaging   | 0.95     | KIF1A*      | Neuron-specific kinesin involved in axonal transport                | 428           |
| Brain structure               | 0.94     | CXCR6*      | Chemokine receptor involved in glial migration                      | 357           |
| Rheumatoid arthritis          | 0.94     | CTSB*       | Cysteine proteinase linked to articular erosion                     | 359           |
| Ovarian cancer                | 0.93     | HSPG2*      | Ovarian tumor suppressor  | 268           |
| Multiple sclerosis            | 0.93     | ZP1*        | Known autoantigen   | 153           |
| ADHD                          | 0.93     | PDLIM5*     | Neuronal calcium signaling  | 328           |
| Breast cancer                 | 0.88     | MAP3K1*     | Response to growth factors  | 158           |
| Amyotrophic lateral sclerosis | 0.88     | CNTN4       | Neuronal cell adhesion  | 306           |
| Schizophrenia                 | 0.81     | FXR1*       | Cognitive function  | 120           |
| Type 1 diabetes               | 0.75     | ACAD10*     | Mitochondrial oxidation of fatty acids                              | 343           |
| Lupus                         | 0.74     | STAT4       | Mediates IL-12 immune response and T <sub>H</sub> 1 differentiation | 113           |

**#5**


**A significant fraction of GWAS  
variants falling in regulatory  
DNA directly affect TF  
occupancy**

# Disease/trait variants specify allelic chromatin states





# Disease/trait variants specify allelic chromatin states




Overall, 20.5% of GWAS SNPs exhibit significant allelic imbalance

For those with high sequencing depth (>200x), **38.7%**

#6

**Disease-associated variants  
cluster in regulatory  
pathways and form  
regulatory networks**


# Within regulatory DNA, disease-associated variants systematically localize within relevant TF recognition sites



# Targets of transcription factor in promoters and enhancers



# Disease variants cluster in regulatory pathways




# Mendelian



# Common




# ~25% of rGWAS inflammatory disease variants lie in IRF9 pathway



$P < 1.6 \times 10^{-13}$


# A common regulatory network for autoimmune disease



$$P < 1.3 \times 10^{-36}$$




# A common regulatory network underlies diverse malignancies




**#7**

**Many, many more variants  
show these effects than  
so-called genome-wide  
significant SNPs**


# Selective enrichment of GWAS variants in pathogenic cell types




# Selective enrichment of GWAS variants in pathogenic cell types



# Selective enrichment of GWAS variants in pathogenic cell types



# Selective enrichment of GWAS variants in pathogenic cell types



# Summary & Implications

Systematic localization of disease-associated variation in regulatory DNA

→ *Enables a coherent approach to understanding the role of non-coding variants*

Significant majority of variants localize in fetal-stage regulatory DNA

→ *Developmental contribution to common adult disorders and traits*

Common networks connect disorders within broader disease classes

→ *Shared genetic liability at the level of transcription factor networks*

Many GWAS data are untapped

→ *Many additional disease-associated variants that do not meet “genome-wide significance” also localize within regulatory DNA*

Deep maps of regulatory DNA in *normal* cells enable pathogenic insights

→ *Pathogenic cell types for many disorders are not well-defined*

# Acknowledgements

## Analysis

Matthew Maurano, Rich Humbert, Eric Rynes  
Eric Haugen, Richard Sandstrom, Audra Johnson,  
Eric Haugen, Alex Reynolds, Bob Thurman

## Data production

Raj Kaul, Scott Hansen, Peter Sabo,  
Molly Weaver, Theresa Cantwell, Kristin  
Lee, Shinny Vong, Vaughan Roach, Erica  
Gist, Sandra Stehling-Sun


## Collaborators

Ian Glass (UW Birth Def. Res. Lab)  
Shelly Heimfeld (FHCRC)  
Nona Sotoodehia and Jen Brody (UW Cardiology)  
Chris Cotsapas (Yale)  
Shamil Sunyaev (Harvard)

**Funding:      NHGRI (ENCODE)**  
**NIH Common Fund (Roadmap Epigenomics)**



# Linking regulatory DNA with its cognate gene(s)




Applied to 1,524,865 DHSs across 79 cell types  
(DHSs $\pm$ 500kb)



580,000  
co-regulated DHSs

# Correlated DHS-promoter pairs physically interact



## A Platelet count

